ZLAB | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 3%

Liquidity 75%

Performance 0%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

6.08%

1 Month

5.97%

3 Months

2.57%

6 Months

-37.63%

1 Year

-46.35%

2 Year

1.98%

Key data

Stock price

$19.54

P/E Ratio

0.00

DAY RANGE

$19.02 - $19.73

EPS

-$0.16

52 WEEK RANGE

$15.96 - $44.34

52 WEEK CHANGE

-$43.67

MARKET CAP

25.777 B

YIELD

N/A

SHARES OUTSTANDING

1.414 B

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

08-05-2025

BETA

0.57

PUBLIC FLOAT

AVERAGE 10 VOLUME

$777,894

AVERAGE 30 VOLUME

$645,953

Company detail

CEO: Ying Du
Region: US
Website: zailaboratory.com
Employees: 1,950
IPO year: 2017

Issue type: American Depository Receipt (ADR’s)
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia. It also develops Odronextamab, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer

ZLAB - Zai Lab Ltd